Loading comparison data...
Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Compare IPILIMUMAB (YERVOY) and PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH (KEYTRUDA QLEX) — clinical data, side effects, and patient experiences.
YERVOY, Yervoy · Immune Checkpoint Inhibitor
How it works
12.1 Mechanism of Action CTLA-4 is a negative regulator of T-cell activity. Ipilimumab is a monoclonal antibody that binds to CTLA-4 and blocks the interaction of CTLA-4 with its l...
Approved for
KEYTRUDA QLEX, Keytruda · Immune Checkpoint Inhibitor
How it works
12.1 Mechanism of Action Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation and cytokine production. Upregulation of...
Approved for
Estimated frequency (%) based on clinical trial data
Based on 9 Reddit discussions
IPILIMUMAB
44%
positive
9 threads
PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH
0%
positive
0 threads
% of discussions mentioning each side effect
9 Reddit threads analysed for IPILIMUMAB
Overall Sentiment
Mixed
Comparison Threads
0
Avg Post Score
54 upvotes
Most discussed side effects in community
Last Updated: May 11, 2025 In order to advance research and acquire treatments, it is necessary we participate in clinical trials whenever possible. The faster these trials are completed, the faster we can get treatments. If you are able, please consider looking through this guide to find a trial th
Hello everyone: I am writing this post, I guess, because I wanted to share my experience with anyone who might have questions about melanoma from someone who’s been through almost everything modern treatment can throw at me. I’ve also done some peer support volunteering, and have experienced firstha
With the commitment of the [$30 million funding from Yorkville Advisors Global](https://www.cytodyn.com/newsroom/detail/649/cytodyn-secures-30-million-commitment-from-yorkville), CytoDyn continues to pursue its goals and ambitions, not just in ColoRectal Cancer, but in all its endeavors. Who signed
Oncotelic is an immuno-oncology company based out of California, with over 30 years of experience in their management team, they have dedicated themselves to developing the first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. A they have filed over
Hellllloooo From (thankfully not sunny) London 🌧️ So… I moved to London on 12th Jan for a fresh start New chapter. Big city energy. Maybe a bit of culture. Maybe a coffee that costs more than my first car. Juggling which job offer to take and which house to choose to get us out of the Airbnb. Inst
I've been posting here for a bit, so I thought I should share my story as well. I hope it helps someone in their journey. It's a super long one, because I love writing stories, and it's super easy when it was factual and I was present for all of it. If you want a TD;LR version, I had colon cancer. I
11/17/2018 - Copy of blog found at martinshkreli.com Biopharma/Investing ————————— Celgene deep-dive is progressing smoothly. I’ve skimmed hundreds of papers (4000 Revlimid entries in Pubmed), docket entries and more in preparation. Thanks for the crazy amount of mail. Fascinating, if not desperate,
Financials, Market Cap: 38.999M USD Current Price: 0.1100 USD 52 Week Range: 0.0800 - 0.2600 USD Average Volume: 228,763 (As of July 14th, 2022) ​ [https://ca.finance.yahoo.com/quote/OTLC?p=OTLC&.tsrc=fin-srch](https://ca.finance.yahoo.com/quote/OTLC?p=OTLC&.tsrc=fin-srch) &#x
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
No community discussions found for PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH yet.
Both IPILIMUMAB and PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH belong to the Immune Checkpoint Inhibitor class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. IPILIMUMAB is administered via Intravenous, whereas PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH uses Subcutaneous. Route of administration can affect onset of action and patient adherence.
IPILIMUMAB carries 4 FDA warnings. PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..
This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.